Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónUS2868691 A
Tipo de publicaciónConcesión
Fecha de publicación13 Ene 1959
Fecha de presentación21 Mar 1956
Fecha de prioridad21 Mar 1956
Número de publicaciónUS 2868691 A, US 2868691A, US-A-2868691, US2868691 A, US2868691A
InventoresIrving Porush, Maison George L
Cesionario originalRiker Laboratories Inc
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine
US 2868691 A
Resumen  disponible en
Imágenes(4)
Previous page
Next page
Reclamaciones  disponible en
Descripción  (El texto procesado por OCR puede contener errores)

United States Patent SELF-PROPELLING COMPOSITIONS FOR INHALA-I TION THERAPY CONTAINING A SALT OF ISO- PROIERENOL R EPINEPHRIYE Claims. (Cl. 167-54) This invention relates to novel medicament-containing,

self-propelling compositions for inhalation'therapy.'-

A number of previous eflorts have been directed to the preparation of medicament-containing, pharmaceutical preparations for use in inhalation therapy. Thes'e preparations suffer from one or more shortcomings. In many cases they require cumbersome mechanical devices to dispense the medicament. Some of these devices employ a rubber airbulb to aspirate the medicament. This often requires substantial physical effort on the "part of the user. In other cases the vehicle for the medicament may possess irritating properties which mitigate against the use of the compositions for inhalation therapy where delicate mucous membranes may be aflected. In some cases Where a fixed dosage is required these'compositions are not conveniently dispensed in measured, constant amounts. For these reasons, as well as others, the benefits of inhalation therapy have not'been fully realized and progress in this mode of medication has lagged.

It is, therefore, one object of this invention to overcome the disadvantages of the prior art compositions invide a self-propelling therapeutic composition for inhalation therapy which maybe packaged with safety in suitable low pressure containers,;such as frangible containers, or in containers having a dispensing valve construction which will permit dispensing jmeasui'ed, constant doses of "the medicament.

Still another object of the present invention is to provide a stable therapeutic composition containing a liquified non-toxic propellent material which is not subject to erratic pressure variations and which imparts easily controlled pressures at room or ambient temperatures to the container in which the composition is stored and dispensed from.

Other objects will be apparent to those skilled in the .art from reading the description which follows.'

The self-propelling compositions of the present invention comprise a medicament dissolved in a non-toxic,

liquid propellant in thenature of a fluorinated or fluorochlorinated lower aliphatic hydrocarbon, preferably with the aid of a co-solvent for both the medicament and the a medicament in aerosol form for inhalation therapy.

'monochlorotrifluoromethane (Freon l3) "ice In carrying out the invention it is contemplated that the non-toxic, liquid propellant shall be a fluorinated or a fluorochlorinated lower saturated aliphatic hydrocarbon, and preferably a halogenated alkane containing not more than 2 carbon atoms and at least 1 fluorine atom, or mixtures thereof. The preferred halogenated lower alkane compounds may be represented generally by the formula C H Cl F wherein an integer less than 3, n is an integer or zero, yis aninteger or zero, and z is an integer, such that n+y+z=2m+2. The propellants shall possess a boiling point of less than F. at 760 mm. pressure. Examples of the propellantsare dichlorodifiuoromethane (Freon 12), dichlorotetrafluoroethane (Freon 114) CCIF CClF trichloromonofluoromethane (Freon 11), dichloromonofiuoromethane (Freon 21), and Propellants with improved vapor pressure characteristics may be obtained by using certain mixtures of these compounds, e. g., Freon 11 and Freon 12, or Freon 12 and Freon 114, For example, dichlorodifluoromethane, which has a vapor pressure of about 70 pounds per square inch .gauge and 1,2-dichloro-1,1,2,2-tetrafluoroethane (Freon 114), with a vapor pressure of about -13 pounds per square inch. gauge at 70 F., may be mixed in various proportions to form a propellant having an intermediate vapor pressure which is well suited for use in relatively low pressure containers.

It is desired that the vapor pressure of the propellant employed shall itself be between about 25 and 65 pounds per square inch gauge at 70 F., and preferably between about 30 and 40 pounds per square inch gauge at that temperature. A one-component propellant defined'for use in thecomposition was found to give a'composition with gaugepressures in the rangeof 55to 65 pounds per square inch at 70 F., which are usable safely with metal containers. The two-component propellants, such as equalweight mixtures of Freon 12 and "Freon 11, were found to give gauge pressures in the range of 2 0 to 40 pounds per square inch at 70 F., which are usable safely with specially reinforced glass containers.

The medicament employed in a composition according to this invention can be one which is therapeutically ef fective when administered'by inhalation and which may be brought into stable solution in any of the above defined liquified propellants, if necessary, with the aid of a cosolvent and/ or stabilizing substance. One type of medicament which can be employed satisfactorily is the vasoconstrictive amines and their acid-addition salts. However, other types of medicaments, such :as hormones, enzymes, alkaloids, steroids, analgesics, broncho-dilators,. antihistamines, 'antitussives, anginal preparations, antibiotics and sulfonamides and synergistic combinations of these,v

may be employed successfully. Examples of the medicaments which may be employed in producing the compositions of this invention are: isoproterenol hydrochloride [u-(isopropylaminomethyl) protocatechuyl alcohol], phenylephrine, epinephrine, ephedrine, narcotine, codeine, atropine, ergotamine, scopolamine, colchicine, cortisone and alkyl nitrites, such'as amyl nitrite or octyl nitrite.

The co-solvent maybe any liquid substance which assists in. dissolving the medicament in the liquified propellant and which is chemically inert to the medicament in the sense that it does not promote the decomposition of this substance. Suitable co-solvents are intermediate in polarity between the propellant and the medicament.

The co-solvents have the property of being a solvent for the medicament and soluble in the propellants prescribed for use in this invention. The co-solvent beside being chemically inert toward the medicament, should benontoxic andwithout undesirable effects on inhalation in the amount present in the aersol produced. The co-solvent shall have as low a boiling point as possible and prefer-. ably not higher than 212 F. at atmospheric pressure. Examples of satisfactory co-solvents include non-toxic loweralcohols and eth ers, e. g., ethanol, diethyl ether, chloroform, mixtures of ethanol and wate r, and mixtures of chloroform and ethanol.

The stabilizers or anti-oxidants which .may be employed are stronger reducing agents than the medicament and which are non-toxic, such as the alkali-metal bisu'lfites (sodium bisulfite), alkali-metal ascorbates (sodium ascorbate), ascorbic acid, nordihydroguaiaretic acid, 2- tertiarybutyl-4-hyd'roxy anisole, 3-tertiarybutyl-4-hydroxy anisole, butylated hydroxytoluene' (sold under the trademark Tenox BHT), ethylhydro-caffeate, etc. It is normallynot necessary to employ -a stabilizer in an amount in excess'of 0.25% by-weight ofthe composition.

One of the important features of this invcntionisthe discovery that the components 'ofthe compositions must be present within certain critical proportions, as otherwise the benefits of the invention are not obtained. One of the most important characteristics of a spray product is the spray pattern. Spray pattern involves the delivery rate, the particle size distribution and the spray angle. The spray pattern is affected by mechanical factors, e. g., valve construction and orifice size and shape, and by the characteristics of the composition, e. g., viscosity, vapor pressure, type and percentage of propellant. For example, where less than the minimum proportion of pro= pellant is employed, thecomposition lack-suificient propellent force and consequently the'inadequate aerosolization of the medicament results in a particle size distribution which is not efiiciently absorbed in-the' bronchioles and alveoli. Where more than the allowable maximum proportion of propellant is employed, the composition may become unstable during storage and-the medicament may precipitate from the composition. Also, thecompositions may develop undesirably high pressures.

into an open container. The open container and its contents are then cooled, preferably to a temperature below the boiling point of the propellant to be employed. A temperature of 25 F. is usually satisfactory. A measured quantity of the liquified propellant which also has been cooled below its boiling point is then introduced into the container and mixed with the solution already present. The quantities of the components introduced into the container are calculated to provide the desired concentration of each in the final composition. Without permitting the temperature of the container and its contents to-rise above the boilingpoint of the propellant, the container is sealed with a closure equipped with asuitable dispensing valve arrangement. Upon warming to room temperature the Q mnts of the container are mixed by agitation of the containerto insure complete solution of the medicament. The sealed container is then ready to dispense the composition and provide the medicament naerosol form- In prder more clearly to disclose the nature of the present invention, the following examples illustrating compositions in accordance with the invention will now be described. ;It sohuld be understood, however, that this is done, solely by way of example and is intended neither to delineate the scope of the invention nor limit the. ambitofthe appended claims. .In the examples which follow, the processdescribed above was employed. In the cxampleswhich follow and throughout the specification, the quantities of material are expressed in termsof One I of the essential characteristics of the compositions of'this I invention is that the medicament shall remain'dissolved and uniformly dispersed throughout the composition. To this end a co-solvent is often necessary in order to maintain the medicament in the dissolved, uniformly dispersed state, both at the time the compositions are prepared and during normal periodsand conditions of storage.

While the proportions of components may varysomewhat depending upon the specific medicament and liquificd propellant employed, in general it has been found desirable that the liquid propellant constitute at least about 50% by weight of the total composition upward to about 90%. It is preferred that the propellant constitute between about 55% or 60% and 80% by weight of the total composition. The amount and constitution of the co-solvent is largely dependent upon the solubility characteristics of the medicament employed. In most cases it has been found that satisfactory results are obtained where the co-solvent constitutes between about 5% or 10% and 40%, and preferably between abont 20% and 40%'-- v we hto the t a .cQmP s t Qn- .lf to! to ch c -so n s s e hanol; is us th int rnattern ,is affected, resulting-in a wetsprayor stream rather thanan aerosol cloud. The amout of medicament shall generally constitute from about 0.1% to 20%, and preferably from about 0.1% to 2% by weight of the'composition. Desirably the propellant makes-upthe difference 'betwen the proportions of medicamennco-solvent, stabilizer and 100%.

"The novel compositions of the-invention maybe-prepared and containers filled with them by-means of-the following process:

Asuitable measured quantity-of the medicament-is mixed with, and dissolved in, a measured amountof the co-solvent. .A stabilizer, if desired,- is added. A- measured quantity-zof the resultingsolution isythea ntra used percentages bysweight of the total composition.

E le

P s-.4 1 Isoproterenol H61 0.25 ate 11.

thane? wer I fluerqmohaa wn 211-.-

Example 2 v Percent Isoproterenol HCl 2 0.25 Water V i 1. 5 Ethanol (absolute) 33.25 Dichlorotetrafluoroethane (Freon 114) 40 Dichlorodifluorornethane (Freon 12) 25.0

Example 3 I Percent Isoproterenol l ICl ate Ethan We Trichloromonotiuoromethane (Freon 1-1) Example 6 g 1 V H Percent Narcotine v 1 Water 0.65 Ethanol (absolute) a 12.35 Chloroform 20.6 Dichlorodifiuorornethane (Freon 12) i f-'3 4.8 Dichlorotetrafluoroethane (Freon 114) 30.6

' -Example 7 p t A Percent Nicotine "1 Ethanol 95% T 34 Dicblorodifiuoromethane (Freon 12) 25 Dichlorotetrafluoroethane (Freon 114) 40 g 100 --Example 8 i r Q 'Percent Isoproterenol HCl 0.25 Water 1 1.5 Ethanol (absolute) 33.25 Dichlorotetrafluoroethane-(Freon- -1 14) 45.5 Dichlorodifluor ometha'ne (Freon 12.) 19.5

Example 9 I Percent Octyl nitrite 0.1- Ethanol 95% p 20 Dichlorotetrafluoroethane (Freon 114) 49.2 Dichlorodifluoromethane (Freon '12) 30.7

Example 10 I I I P ercent Atropine 0.1 Ethanol 95% a 9.9 Dichlorodifluoromethane (Freon 12) 45 Dichlorotetrafluoroethane (Freon 114) 45 1 100 Example 11 i t Percent Octyl nitrite 0.1 Ethanol 95 9.9 Dichlorotetrafiuoroethane .(Freon 114) 55.4 Dichlorodifiuoromethane (Freon 12) 34.6

Y 100 Example 12 Percent O ctyl nitrite 0.1 Diethyl ether 14.9 'Dichlorotetrafluoroethane (Freon 114) 45 Dichlorodifluoromethane (Freon 12) 40 Other medicaments than those employed in the above examples may be used, such as ergot-amine, scopolamine,

" colchicine, cortisone, amyl nitrite, etc.

' is liquified and cooled at 25 F., added to the chilled concentrate and mixed in. Keeping it at the same temperature, the mixture is measured into the container to 4' be filled and the container is sealed with a closure equipped with a suit-able dispensing valve arrangement. An alternative process, known as pressure filling," is paricularly suitable where the closure employed has, a special valve construction, for'example, that of the type disclosed .in U. S. Patent 2,721,010, issued Octoberl8, 1955. Such a valve' construction permits dispensing a measured dose of medicament'in aerosol form;

It is desirable to enclose the composition in accordance with this invention in apressure-tight container having a suitable outlet valve secured in an opening in the top wall of the container. With the compositions of the invention the pressure rangeis such that it is permissible to use glass bottles instead of metal containers. The compositions and the bottles are characterized by a clear, sparkling appearancewith the advantage that it is easy to observe when the'container is nearly empty. It is recommended for added safety that the glass bottles be coated with a plastic film, preferably clear. 'Aldip-tube of suitable material may be connected with the opening containing the valve arrangement and extendingfto the bottom of the container or an inverted system without a dip-tube may be'-used.-- Upon opening the valve the composition is expelled through the opening in the form of a fine stream to form an aerosol of the medicament. Toaccomplish suitable aerosolization of the medicatnent the opening is desirably constructed to provide a small orifice so as to expel a fine spray of the composition., The container just described is typical of thesecalled aerosol bomb. One typical form of device which iseminently satisfactory for dispensing accurately measured quantities of the medicament in a suitable aerosol form and insuring eflective administration is that disclosed in our copending' application entitled, Aerosol Dispensing Apparatus, Serial No. 572,965,--filed concurrently with this application. I "The terms and expressions which we have employed are used as terms-of description and not of limitation, and we have no intention, in the use of suchterms and expressions, of excluding any equivalents of the features shown and described or portions thereof, but recognize that various modifications are possible within the scop of the invention claimed.

, .What is claimed is: a

1. A self-propelling pharmaceutical composition capable of providing a medicament in aerosol formsuitable for inhalation therapy, comprising as the medicament a water-soluble acid-addition salt of a bronchodi lator amine selected from the class consisting of isoproterenol and epinephrine, said medicament comprising between about 0.1% and 2% of the composition, as a co solvent for said medicament, an aqueous ethanol mixture in an amount comprising between about 20% to 40% of the composition, the water in said cosolvent comprising between about 1.5% and 2% 'of the total com'-' position, and as a liquefied non-toxic propellant componut 21 halogenated lower alkane containing at least 1 fluorine atom and not more than 2 carbon atoms and having a vapor pressure of between about 20 and 65 pounds per square inch gauge at F., said liquefied propellantfcomponent comprising substantially the re mainder of the composition.

2.- A self-propelling pharmaceutical composition as defined by claim 1, wherein the liquefied non-toxic propellantcomponent comprises a mixture of said halogenated lower alkanes.

3. A self-propelling pharmaceutical composition as defined by claim 1, wherein the liquefied non-toxic propellant component has a vapor pressure of between about a 20 and 40 pounds per square inch gauge at 70 F.

4. A self-propelling pharmaceutical composition as defined by claim I, wherein the liquefied non-toxic propellant component is selected from the group consisting of dichlorodifluoromethane and a mixture of dichlorodifiuoromethane and dichlorotetrafiuoroethane.

'5. A self-propelling pharmaceutical composition as deinedby c im. 1, whe e h m c m compr se a water s'oliibleiacid addition salt of epinephrine.

Aseiep o onia pharmaceutical composition as defined by claim 1, wherein the medicament comprises isoproterenol hydrochloride.

,8 A s lfr e lin ha a tica c m osi as. efi y fs i .1. he e n th h q sam nt om ses epinephrine hydrochloride.

se -swellin Ph r aceut ca o po t on si efined by claim '1, containing about 0.2% isoproterenol hydrochloride, about 2% wate about 37.8% ethanol, 3 91 .39 li uefied tsi hls qmh ofluorom hane. and shq li e i d. is lomdiflu sm th .A- Ql -Pmps in pharm seu l mp sition as defined'by claim 1, containing about 0.25% epinephrine, about 0.5%,oj a 3% .normal solution ofhydrochloric acid, about 0.15% ascorbic acid, about; 1% a ditional-water, about 33. 1%, ethanol, about 25% liquefiedv dichlorodisfiuoromethane, and about 40% liquefied ,dichlorotetra: fluoroethane.

11 A self-propelling pharmaceutical composition as defined by claim .1 containing about 0.25% ,isoprotera enol hydrochloride, about-1.5% water, about 33.25%- ethanol, and the remainder being a liquefied'non-toxie propellant as ,defi ne d by claim 1.

12. Asel-f-propelling pharmaceutical composition as definedby claim 11, containing about 0.25%l.isoproter-. enol hydrochloride, about 1.5% water, about "33.25% ethanol, and the remainder being liquefied dichlorodifluoromethane. i 13. A self-propelling pharmaceutical composition as defined by claim 11, containing about 0.25% isoproterenol hydrochloride, about 1.5 water, about 33.25% ethanol, about 40% liquefied dichlorotetrafiuoroethane, and-about 25% liquefied dichlorodifluoromethane. V

14. A package comprising a pressure-tight container having a valve-controlled opening and containing a selfpropelling pharmaceutical composition capable of providing a medicament in aerosol form suitable forinhal-ation therapy, comprising as a medicament a water-soluble acid-addition salt ofa bronchodilator' amine selected from the. class consisting of. isoproterenol and epinephrine,- said medicament comprising between about 0.1% and 2% of the composition, as. a .cosolvent-for said medicament an aqueous ethanol mixture. in an. amount comprising- -betwee about 20%. and 40% of the composition, the waterin said cosolvent comprising between about 1.5% and 2% of the total. composition, and as a liquefiedinontoxic propellant component a halogenated lower allgane containing at least '1 fluorine atom and not more that-n2 carbon atoms and. having a vapor pressure ofbetween abqutZO: and 65 pounds per square inch gauge at- 70" =F.',

8 said liquefied propellant component comprising substantia l lythe remainder of the composition.

15. A method oi producing a measured dose ofimedicament in aerosol form suitable for inhalation therapy whi omprise f rm n a q d mposition oira' msdis mentqnthetorm o a atqrs luhleaci d ition altof abronchodilatoramine selected from the class consisting otisoproterenol and epinephrine, said medicamom. comprising between about 0.1% and 2% of the composition, said medicament being dissolved ina mixture of a co-solvent and a liquefied non-toxic propellant component, said co-solvent comprising an aqueous ethanol gniggtpre i n an amount comprising between about 2 1 and 49% oi the total. c mpos the Waterfih said nqns9lve n t comprising between about l.5'%.wand'2%' or the total composition, said liquefied non-toxic; propellant component comprising a halogenated lower alkane containing at least 1 fluorine atom and not more than 2 carbon atoms and having a--.v-ap,or pressure of between ab9u-t'20 and pounds per square inch gauge at F., said liquefied propellant component comprising substan-v a ly e .remainder ofthe. composition,v .and dispensing he. l iq isl .qq l position. from. a. pressure-tight. container through a control valve for-self-propelled delivery in the f rm of an. a lQS01' l'QSU1l1l1g from the rapidvaporization of...the propellant.

References Cited in thefile 'of this patent UNITED STATES PATENTS 2,232,976- Fox Nov. 26,1240,

Fulton: Propellents for Low-Pressure Liquefied Gas Aerosols, Ind. and Eng. Chem, vol. 40, No. 4, April 1948, pp. 699 and 700.

Fulton: Germicidal Aerosols, Soap and Sanitary Chemicals, May 1948, pp. -127, 157 and 1 59..

Mina-z Glass-Aerosols for Cosmetics, Amer. Peri. and'EsscOil Rev- Iune 1954, pp. 429-31;

Downing:- Formulation of- Aerosol Products, Soap and; Sanitary Chem., September 1953, pp. 142, 143, 145, 147; 149, 153, 155, 177 and 178.

U. S. Disp., 25th Ed., J; B. Lippincott Co., pp. 38 and 39,- Philadelphia, Pa.

Drugand Cos. Ind., vol. 65, No. 4, October 1949,. pp, 396-98-and- 470-73. I

New'and- Non-oificial Remedies, J. B; Lippincott Co.,v Philadelphia, Pa., 1955, pp. 225-227;

Merck Index, 6th ed., Merck and Co., Inc., 1952, pp. 72, 73, 387-89, 664 and, 674-75..

Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
US2222976 *15 Nov 193726 Nov 1940Sharp & Dohme IncNasal drops
US2728495 *19 Abr 195127 Dic 1955Little Inc ALiquid dispensing device and composition therefor
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US3039928 *17 Mar 196019 Jun 1962Abbott LabStable aqueous isoproteronol compositions
US3039929 *17 Mar 196019 Jun 1962Abbott LabStable isoproteronol compositions
US3050443 *16 Feb 196021 Ago 1962James F SchuylerHeadache remedy containing ammonia
US3051621 *22 Oct 195928 Ago 1962Grove Lab IncGel composition, pressurized container with same, and method of preparation
US3088874 *23 May 19607 May 1963Union Carbide CorpPowder aerosol
US3155574 *24 May 19623 Nov 1964RevlonAerosol composition
US3169095 *30 Oct 19629 Feb 1965Rexall Drug ChemicalSelf-propelling powder-dispensing compositions
US3282781 *25 Nov 19601 Nov 1966Merck & Co IncInhalant compositions
US3341604 *28 Ene 196312 Sep 1967Exxon Research Engineering CoColor stable ketone solvent composition
US3710782 *1 Oct 196916 Ene 1973Hauser Res And Eng CoMethod of treating human skin with a composition for electromedical applications
US4352789 *17 Mar 19805 Oct 1982Minnesota Mining And Manufacturing CompanyAerosol compositions containing finely divided solid materials
US4576949 *7 May 198418 Mar 1986The Upjohn CompanyUse of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
US4919919 *14 Sep 198824 Abr 1990Nippon Kayaku Kabushiki KaishaNitroglycerin spray
US5118494 *13 Mar 19912 Jun 1992Minnesota Mining And Manufacturing CompanyUse of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5175152 *28 Sep 199029 Dic 1992Singh Nikhilesh NComposition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5225183 *30 Ene 19916 Jul 1993Riker Laboratories, Inc.Medicinal aerosol formulations
US5292884 *13 Oct 19928 Mar 1994Biomide Investment Limited PartnershipCyclic hydroxamic acids
US5439670 *2 Jul 19938 Ago 1995Riker Laboratories, Inc.Medicinal aerosol formulations
US5514713 *2 Dic 19947 May 1996Ono Pharmaceutical Co., Ltd.Amidinophenol derivatives
US5534536 *23 Ago 19949 Jul 1996Ono Pharmaceuticals Co. Ltd.Fused phenol derivatives
US5605674 *31 May 199525 Feb 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5653962 *19 May 19955 Ago 1997Glaxo Group LimitedAerosol formulations containing P134a and particulate medicaments
US5658549 *19 May 199519 Ago 1997Glaxo Group LimitedAerosol formulations containing propellant 134a and fluticasone propionate
US5674471 *19 May 19957 Oct 1997Glaxo Group LimitedAerosol formulations containing P134a and salbutamol
US5674472 *19 May 19957 Oct 1997Glaxo Group LimitedCanisters containing aerosol formulations containing P134a and fluticasone propionate
US5674473 *31 May 19957 Oct 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5676929 *19 May 199514 Oct 1997Glaxo Group LimitedCanister containing aerosol formulations containing P134a and particulate medicaments
US5679287 *28 Abr 199521 Oct 1997Great Lakes Chemical CorporationUses of heptafluoropropane
US5681545 *31 May 199528 Oct 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5683676 *19 May 19954 Nov 1997Glaxo Group LimitedCanister containing aerosol formulations containing P134a and particulate medicaments
US5683677 *31 May 19954 Nov 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5695743 *4 Mar 19939 Dic 1997Riker Laboratories, Inc.Medicinal aerosol formulations
US5720940 *31 May 199524 Feb 1998Riker Laboratories, Inc.Medicinal aerosol formulations
US5736124 *30 May 19957 Abr 1998Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US5744123 *5 Jun 199528 Abr 1998Glaxo Group LimitedAerosol formulations containing P134a and particulate medicaments
US5750544 *19 Abr 199612 May 1998Ono Pharmaceuticals Co., Ltd.Fused phenol derivatives
US5766573 *16 Ene 199716 Jun 1998Riker Laboratories, Inc.Medicinal aerosol formulations
US5776432 *31 May 19957 Jul 1998Minnesota Mining And Manufacturing CompanyBeclomethasone solution aerosol formulations
US5776433 *31 May 19957 Jul 1998Minnesota Mining And Manufacturing CompanyFlunisolide aerosol formulations
US5785952 *12 May 199528 Jul 1998Glaxo Group LimitedAerosol medicament formulation having a surface coating of surfactant
US5817293 *30 May 19956 Oct 1998Glaxo Group LimitedCanister containing aerosol formulations containing P134a and particulate medicaments
US5840213 *14 Mar 199724 Nov 1998Great Lakes Chemical CorporationUses of heptafluoropropane
US5861268 *23 May 199619 Ene 1999Biomide Investment Limited PartnershipMethod for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US5891419 *21 Abr 19976 Abr 1999Aeropharm Technology LimitedEnvironmentally safe flunisolide aerosol formulations for oral inhalation
US5891420 *21 Abr 19976 Abr 1999Aeropharm Technology LimitedEnvironmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5916540 *6 Abr 199829 Jun 1999Glaxo Group LimitedAerosol formulations containing P134A and/or P227 and particulate medicament
US5919435 *12 May 19956 Jul 1999Glaxo Group LimitedAerosol formulation containing a particulate medicament
US5922306 *15 Abr 199813 Jul 1999Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US5980867 *6 Jul 19989 Nov 19993M Innovative Prperties CompanyFlunisolide aerosol formulations
US6022893 *7 Ago 19968 Feb 2000Ono Pharmaceutical Co., Ltd.Hydroxamic acid derivatives
US6054488 *2 Jun 199825 Abr 20003M Innovative Properties CompanyMedicinal aerosol formulations of formoterol
US6129905 *13 Ago 199710 Oct 2000Aeropharm Technology, Inc.Aerosol formulations containing a sugar as a dispersant
US6136294 *22 Sep 199824 Oct 2000Aeropharm Technology Inc.Amino acid stabilized medical aerosol formulation
US62005499 Mar 199913 Mar 2001Glaxo Group LimitedAerosol formulation containing P134a and particulate medicament
US622133910 May 199924 Abr 2001Glaxo Group LimitedMedicaments
US62386472 Nov 199929 May 2001Glaxo Group LimitedAerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane
US625136817 Jun 199726 Jun 2001Glaxo Group LimitedPharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant
US630310314 Jun 200016 Oct 2001Glaxo Group LimitedAerosols containing salmeterol xinafoate and an anticholinergic medicament
US630636824 Nov 199823 Oct 2001Glaxo Group LimitedAerosol formulation containing a particulate medicament
US630636928 Abr 200023 Oct 2001Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US63330231 May 200025 Dic 2001Glaxo Group LimitedAerosol formulation containing particulate formoterol, propellant and polar cosolvent
US634623229 Mar 200012 Feb 20023M Innovative Properties CompanyMethod of forming conductive lines
US635268428 Abr 19985 Mar 2002Riker Laboratories Inc.CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant
US641674330 Ago 20009 Jul 2002Schering CorporationAerosol formulations of albuterol and 1,1,1,2-tetrafluoroethane
US645833817 Jul 20001 Oct 2002Aeropharm Technology IncorporatedAmino acid stabilized medicinal aerosol formulations
US64615912 Feb 19988 Oct 2002Jago Research AgMedical aerosol formulations
US64754672 Ago 19995 Nov 2002Jago Research AgMedicinal aerosol formulations
US65034828 Jun 19927 Ene 2003Schering CorporationNon-chlorofluorocarbon aerosol formulations
US658595822 Jul 19991 Jul 2003Jago Research AgMedicinal aerosol formulations
US674341331 May 19951 Jun 20043M CompanySuspension aerosol formulations
US689362831 Mar 200317 May 2005Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US691906930 Abr 200319 Jul 2005Glaxo Group LimitedAerosol formulation containing particulate formoterol, propellant and polar cosolvent
US710153431 May 19955 Sep 20063M Innovative Properties CompanySuspension aerosol formulations
US710515231 May 199512 Sep 20063M Innovative Properties CompanySuspension aerosol formulations
US717624015 Jul 200213 Feb 2007Ono Pharmaceutical Co., Ltd.Pentanoic acid derivatives
US749802023 Nov 20043 Mar 2009Glaxo Group LimitedMedicaments
US75664454 Jun 199728 Jul 2009Norton Healthcare LimitedMedicinal aerosols and methods of delivery thereof
US756960829 Jul 20054 Ago 2009Ono Pharmaceutical Co., Ltd.Pentanoic acid derivatives
US756960929 Jul 20054 Ago 2009Ono Pharmaceutical Co., Ltd.Pentanoic acid derivatives
US758228414 Abr 20031 Sep 2009Nektar TherapeuticsParticulate materials
US799419726 Ago 20099 Ago 2011Map Pharmaceuticals, Inc.Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US808023612 Jun 200920 Dic 2011Nektar Therapeutics Uk, LtdParticulate materials
US811963919 Jul 201021 Feb 2012Map Pharmaceuticals, Inc.Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US814837711 Feb 20083 Abr 2012Map Pharmaceuticals, Inc.Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US83573937 Dic 200422 Ene 2013Acrux Dds Pty Ltd.Transdermal delivery rate control using amorphous pharmaceutical compositions
US835769628 Ene 201022 Ene 2013Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US847030111 Nov 201125 Jun 2013Nektar TherapeuticsParticulate materials
US852473422 Oct 20093 Sep 2013Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US852473522 Oct 20093 Sep 2013Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US854642322 Oct 20091 Oct 2013Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US86291396 Oct 200914 Ene 2014Mpex Pharmaceuticals, Inc.Topical use of Levofloxacin for reducing lung inflammation
US872234018 Oct 200713 May 2014Board Of Regents, The University Of Texas SystemJAB1 as a prognostic marker and a therapeutic target for human cancer
US878487811 Dic 201222 Jul 2014Acrux DDS Pty Ltc.Transdermal delivery rate control using amorphous pharmaceutical compositions
US88158386 Oct 200926 Ago 2014David C. GriffithAerosol fluoroquinolone formulations for improved pharmacokinetics
US88283593 Jun 20139 Sep 2014Nektar TherapeuticsParticulate materials
US883484929 May 200916 Sep 2014Norton Healthcare LimitedMedicinal aerosols and methods of delivery thereof
US885327730 Nov 20107 Oct 2014The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesNitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
US932693617 Jul 20143 May 2016Raptor Pharmaceuticals, Inc.Aerosol fluoroquinolone formulations for improved pharmacokinetics
US952214321 Jul 201520 Dic 2016Mitos Pharmaceuticals, Inc.Nitroxides for use in treating or preventing diabetes and obesity
US95221441 Sep 201520 Dic 2016Mitos Pharmaceuticals, Inc.Nitroxides for use in treating or preventing diabetes and obesity
US96160604 Ago 201411 Abr 2017Nektar TherapeuticsParticulate materials
US965020316 Jul 201416 May 2017Norton Healthcare LimitedMedicinal aerosols and methods of delivery thereof
US97005645 Mar 201211 Jul 2017Horizon Orphan LlcUse of aerosolized levofloxacin for treating cystic fibrosis
US971773818 Abr 20161 Ago 2017Horizon Orphan LlcAerosol fluoroquinolone formulations for improved pharmacokinetics
US20030089369 *8 Nov 200215 May 2003Chiesi Farmaceutici S.P.A.Pressurised metered dose inhalers (MDI)
US20030096802 *15 Jul 200222 May 2003Ono Pharmaceutical Co., Ltd.Pentanoic acid derivatives
US20030143163 *11 Mar 200331 Jul 2003Glaxo Group LimitedMedicaments
US20030165437 *31 Mar 20034 Sep 2003Glaxo Group LimitedAerosos formulations containing P134a and particulate medicament
US20030198600 *30 Abr 200323 Oct 2003Glaxo Group LimitedAerosol formulation containing particulate formoterol, propellant and polar cosolvent
US20030223939 *14 Abr 20034 Dic 2003Andreas KordikowskiParticulate materials
US20040033201 *30 Jul 200319 Feb 20043M Innovative Properties CompanyProcess for making chemically stable C-17/21 OH 20-ketosteroid aerosol products
US20040062720 *3 Jul 20031 Abr 2004Chiesi Farmaceutici S.P.A.Pharmaceutical aerosol composition
US20040197273 *9 Abr 20047 Oct 20043M CompanySuspension aerosol formulations
US20050069918 *1 Jun 200431 Mar 2005Francois ClaretJAB1 as a prognostic marker and a therapeutic target for human cancer
US20050089477 *23 Nov 200428 Abr 2005Glaxo Group LimitedMedicaments
US20050107306 *17 May 200419 May 2005Barr Philip J.Treatment of respiratory disease associated with matrix metalloproteases by inhalation of synthetic matrix metalloprotease inhibitors
US20050142071 *18 Feb 200530 Jun 2005Chiesi Farmaceutici S.P.A.Pressurised metered dose inhalers (MDI)
US20050175680 *7 Dic 200411 Ago 2005Acrux Dds Pty Ltd.Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050181032 *23 Dic 200418 Ago 2005Acrux Dds Pty Ltd.Metastable pharmaceutical compositions
US20050186141 *22 Dic 200425 Ago 2005Acrux Dds Pty Ltd.Transdermal aerosol compositions
US20050207991 *9 May 200522 Sep 2005Glaxo Group LimitedAerosol formulations containing P134a and particulate medicament
US20050220717 *22 Feb 20056 Oct 20053M Innovative Properties CompanySteroid solution aerosol products with enhanced chemical stability
US20050232873 *21 Jun 200520 Oct 2005Glaxo Group LimitedAerosol formulation containing particulate formoterol, propellant and polar cosolvent
US20050261371 *29 Jul 200524 Nov 2005Ono Pharmaceutical Co., Ltd.Pentanoic acid derivatives
US20050267167 *29 Jul 20051 Dic 2005Ono Pharmaceutical Co., Ltd.Pentanoic acid derivatives
US20050267168 *29 Jul 20051 Dic 2005Ono Pharmaceutical Co., Ltd.Pentanoic acid derivatives
US20060018840 *28 Jun 200526 Ene 2006Nektar TherapeuticsAerosolizable formulation comprising nicotine
US20060110328 *31 Oct 200525 May 2006Cagle Gerald DMethod of delivering nasal spray
US20060128810 *9 Oct 200315 Jun 2006Kyoto UniversityRemedies for allergic diseases
US20070021323 *21 Sep 200625 Ene 2007Government of the USA, represented by the Secretary,Use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
US20070065370 *27 Oct 200622 Mar 2007Boehringer Ingelheim KgSuspension aerosol formulationis of pharmaceutical products
US20070071803 *31 Ago 200629 Mar 2007Acrux Dds Pty LtdDermal penetration enhancers and drug delivery systems involving same
US20070253913 *13 Mar 20071 Nov 2007Nahed MohsenAerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
US20080064674 *14 Nov 200713 Mar 2008Schering CorporationPharmaceutical Compositions
US20080131494 *30 Oct 20075 Jun 2008Acrux Dds Pty Ltd.Dermal Penetration enhancers and drug delivery systems involving same
US20080287451 *11 Feb 200820 Nov 2008Cook Robert OMethod of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20090104127 *25 Jul 200823 Abr 2009Boehringer Ingelheim KgSuspension aerosol formulations of pharmaceutical products
US20090188491 *16 Ene 200930 Jul 2009Glaxo Group LimitedMedicaments
US20090191134 *12 Jun 200730 Jul 2009Medispray Laboratoriespvt. Ltd.Stable aerosol pharmaceutical formulations
US20090246148 *29 May 20091 Oct 2009Norton Healthcare LtdMedicinal aerosols and methods of delivery thereof
US20100037890 *22 Oct 200918 Feb 2010Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US20100040560 *22 Oct 200918 Feb 2010Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US20100081663 *26 Ago 20091 Abr 2010Map Pharmaceuticals, Inc.Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20100081664 *26 Ago 20091 Abr 2010Map Pharmaceuticals, Inc.Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20100087386 *6 Oct 20098 Abr 2010Mpex Pharmaceuticals, Inc.Topical use of levofloxacin for reducing lung inflammation
US20100087416 *6 Oct 20098 Abr 2010Mpex Pharmaceuticals, Inc.Aerosol fluoroquinolone formulations for improved pharmacokinetics
US20100158957 *28 Ene 201024 Jun 2010Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US20100166673 *22 Oct 20091 Jul 2010Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
US20100166674 *18 Dic 20091 Jul 2010Acrux Dds Pty LtdTransdermal delivery rate control using amorphous pharmaceutical compositions
US20100284940 *19 Jul 201011 Nov 2010Map Pharmaceuticals, Inc.Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20110014134 *27 Sep 201020 Ene 2011Boehringer Ingelheim KgSuspension aerosol formulations of pharmaceutical products
US20110171141 *25 Jun 201014 Jul 2011Kellerman Donald JAdministration of dihydroergotamine mesylate particles using a metered dose inhaler
US20120316246 *17 Jul 201213 Dic 2012Fahl William ETopical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
DE2703119A1 *26 Ene 19774 Ago 1977Fisons LtdDinatriumcromoglycat mit weniger als 5 % wasser und dieses umfassende pharmazeutische praeparate
DE2831419A1 *18 Jul 19781 Feb 1979Fisons LtdAerosol compsn., pref. contg. fine medicament
DE102008007198A11 Feb 200813 Ago 2009Infectopharm Arzneimittel Und Consilium GmbhOral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
EP0148748A2 *4 Ene 198517 Jul 1985Ab LeoImproved snuff and preparation thereof
EP0148748A3 *4 Ene 19857 Ene 1988Ab LeoImproved snuff and preparation thereof
EP0213108A2 *26 Jun 19864 Mar 1987Kurt Dr. BurghartPharmaceutical preparation containing an antihypotonic as the active agent
EP0213108A3 *26 Jun 198615 Jul 1987Kurt Dr. BurghartPharmaceutical preparation containing an antihypotonic as the active agent
EP0703216A119 Sep 199527 Mar 1996Ono Pharmaceutical Co., Ltd.Amidinophenol derivatives as protease inhibitors
EP0757037A229 Jul 19965 Feb 1997Ono Pharmaceutical Co., Ltd.Sulfonylamino acid derivatives as metalloproteinase inhibitors
EP2085071A119 Ene 20095 Ago 2009Infectopharm Arzneimittel und Consilium GmbHOrally or nasally administrable preparations containing epinephrine with improved characteristics
EP2206698A121 Dic 200914 Jul 2010ONO Pharmaceutical Co., Ltd.Ethynylindole compounds
EP2243493A12 Jul 200327 Oct 2010Ono Pharmaceutical Co., Ltd.Immunopotentiative composition
EP2253642A125 Dic 199824 Nov 2010ONO Pharmaceutical Co., Ltd.Polypeptides, cDNAs encoding the same and utilization thereof
EP2255829A222 Jul 20021 Dic 2010Ono Pharmaceutical Co., Ltd.Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
EP2264059A125 Dic 199822 Dic 2010ONO Pharmaceutical Co., Ltd.Polypeptides, cDNAs encoding the same and utilization thereof
EP2270051A222 Ene 20045 Ene 2011Ono Pharmaceutical Co., Ltd.Antibody specific for human PD-1 and CD3
EP2281818A118 Feb 20039 Feb 2011Ono Pharmaceutical Co., Ltd.Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
EP2308562A224 Dic 200413 Abr 2011Ono Pharmaceutical Co., Ltd.Azetidine ring compounds and drugs comprising the same
EP2364982A116 Abr 200414 Sep 2011ONO Pharmaceutical Co., Ltd.Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
EP2385040A112 Mar 20049 Nov 2011ONO Pharmaceutical Co., Ltd.Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
EP2422814A123 Jul 200429 Feb 2012Ono Pharmaceutical Co., Ltd.Remedy for cartilage-related diseases
EP2465537A19 Oct 200320 Jun 2012ONO Pharmaceutical Co., Ltd.Microspheres comprising ONO-1301
EP2465538A220 Oct 200520 Jun 2012Ono Pharmaceutical Co., Ltd.Use of immunesuppressant receptor
EP2481732A131 Ago 20041 Ago 2012Ono Pharmaceutical Co., Ltd.Condensed ring compound and use thereof
EP2508204A225 Jun 200310 Oct 2012Ono Pharmaceutical Co., Ltd.Remedies for diseases caused by vascular contraction or dilation
EP2565178A128 May 20036 Mar 2013Ono Pharmaceutical Co., Ltd.LPA Receptor Antagonists
EP2594272A218 May 200622 May 2013Mpex Pharmaceuticals, Inc.Aerosolized fluoroquinolones and uses thereof
EP2657235A127 Oct 200630 Oct 2013Ono Pharmaceutical Co., Ltd.Compound containing basic group and use thereof
EP2883865A127 Ago 200417 Jun 2015Ono Pharmaceutical Co., Ltd.Compound capable of binding S1P receptor and pharmaceutical use thereof
EP3002285A15 Jul 20116 Abr 2016ONO Pharmaceutical Co., Ltd.Tetrahydrocarboline derivative
EP3115057A120 Oct 200511 Ene 2017ONO Pharmaceutical Co., Ltd.Use of immunesuppressant receptor
WO1992005781A1 *26 Sep 199116 Abr 1992The Procter & Gamble CompanyComposition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
WO1994013262A1 *6 Dic 199323 Jun 1994Boehringer Ingelheim Pharmaceuticals, Inc.Stabilized medicinal aerosol solution formulations
WO1994013263A1 *6 Dic 199323 Jun 1994Jager Paul DStabilized medicinal aerosol solution formulations
WO1996033913A1 *26 Abr 199631 Oct 1996Great Lakes Chemical CorporationNovel uses of heptafluoropropane
WO2004031118A128 May 200315 Abr 2004Ono Pharmaceutical Co., Ltd.Lpa receptor antagonists
WO2004032965A19 Oct 200322 Abr 2004Ono Pharmaceutical Co., Ltd.Endogenous repair factor production promoters
WO2005063704A124 Dic 200414 Jul 2005Ono Pharmaceutical Co., Ltd.Azetidine ring compounds and drugs comprising the same
WO2007049771A127 Oct 20063 May 2007Ono Pharmaceutical Co., Ltd.Compound containing basic group and use thereof
WO2007069565A111 Dic 200621 Jun 2007Ono Pharmaceutical Co., Ltd.Bicyclic heterocyclic compound
WO2007069671A114 Dic 200621 Jun 2007Ono Pharmaceutical Co., Ltd.Bicyclic heterocyclic compound
WO2008136377A125 Abr 200813 Nov 2008Ono Pharmaceutical Co., Ltd.Bicyclic heterocyclic compound
WO2010147133A116 Jun 201023 Dic 2010小野薬品工業株式会社Novel imidazopyridine compound
WO2011066537A130 Nov 20103 Jun 2011The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesNitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
WO2011162222A120 Jun 201129 Dic 2011小野薬品工業株式会社Novel crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid
WO2012074069A11 Dic 20117 Jun 2012小野薬品工業株式会社Novel compound and medical use thereof
WO2012127885A15 Ene 201227 Sep 2012小野薬品工業株式会社Tetrahydrocarboline derivative
WO2013161919A125 Abr 201331 Oct 2013小野薬品工業株式会社Trk-INHIBITING COMPOUND
WO2014129431A118 Feb 201428 Ago 2014小野薬品工業株式会社Trk-INHIBITING COMPOUND
Clasificaciones
Clasificación de EE.UU.222/192, 514/653, 514/645, 424/45, 222/394, 514/343, 514/304
Clasificación internacionalC09K3/30, A61K9/00, A61K31/16, B05B9/00
Clasificación cooperativaA61K9/008
Clasificación europeaA61K9/00M20B6